Loading...
In the Australian D-Health randomized trial, 21,000 community-dwelling older adults (age range, 60–85) received either 60,000 IU of vitamin D3 monthly or placebo for 5 years. Results published in 2022 showed no reduction in 6-year mortality with vitamin D (NEJM JW Gen Med Mar 15 2022 and Lancet Diabetes Endocrinol 2022; 10:120).
Now, the researchers present 5-year fracture outcomes. No significant differences were noted between the vitamin D and placebo groups in total fractures (5.6% and 5.9%; P=0.32) or in nonvertebral, hip, or major osteoporotic fractures. Mean 25-hydroxyvitamin D levels during the trial were about 30 ng/mL in the placebo group and 45 ng/mL in the supplemented group. However, about one quarter of participants had estimate…